Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

An epidemiologic study on the seropositive rate of hepatitis A virus among a selected group of children and adults in Busan

부산지역 소아 및 성인의 A형 간염 바이러스 항체 양성률에 대한 역학적 조사

  • Received : 2006.01.02
  • Accepted : 2007.01.15
  • Published : 2007.03.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : The prevalence of hepatitis A virus (HAV) in a certain community reflects that community's living standards and hygienic conditions. And the pattern of HAV infection differs over time and geography. Recently, a shift in prevalence has been observed in cases from chilhood to adulthood. We studied the HAV antibody prevalence in the general population in Busan. Methods : From October 2004 to March 2005, total 472 subjects were tested for HAV antibodies. All samples were collected from patients in Maryknol Hospital. Results : The overall seropositive rate was 22.8% (108/472). The seropositive rates were 1.7% in subjects aged 2-5 years, 1.7% in 6-10 years, 0% in 11-20 years, 40.5% in 21-30 years, 82.1% in 31-40 years, 94.7% in 41-50 years, and 100% in subjects aged over 50 years. There was no significant gap between gender groups. Conclusion : As the socioeconomic conditions in Korea have improved, the HAV seropositive rate in school-aged children has dramatically decreased in the last 20 years. But, the seropositive rate of HAV didn't differ according to gender. The seropositive rate of HAV in the pediatric group was very low, which suggests the increasing possibility of clinical HAV infection in adults in the near future. Therefore, we should actively prevent the spread of hepatits A virus. In order to do that, we need to reorganize our lifestyle and personel hygiene and carry out active and passive immunization to high risk groups.

목 적 : A형 간염 유병률은 그 지역의 생활환경과 위생상태와 밀접한 관계가 있으며 시간 및 지역에 따라 다양한 양상을 보인다. 최근에 들어와 A형 간염 유병률의 변화에 대하며 많은 이들이 보고하여 왔다. 이에 본 연구는 부산 지역에 거주하는 소아과 성인을 대상으로 A형 간염 항체 유병률을 측정하였다. 방 법 : 부산시에 거주하고 2004년 10월부터 2005년 3월까지 메리놀병원에 입원한 472명을 대상으로 하였으며 전 연령층의 혈청으로부터 면역방사계수 측정법을 이용하여 항 A형 바이러스 IgG 항체 유무를 측정하였다. 결 과 : 1) A형 간염 IgG 항체 양성률은 총 472명 중 108명에서 항체가 검출되어 22.8%이었고, 2-5세가 1.7%, 6-10세가 1.7%, 11-20세가 0%, 21-30세가 40.5%, 31-40세가 82.1%, 41-50세가 94.7%, 51세 이상이 100%로 조사되었다. 2) 각 연령군 모두에서 남녀간의 항체 양성률(P=0.2)간에 유의한 차이는 없는 것으로 나타났다. 결 론 : 우리 나라에서는 최근 경제발전과 더불어 생활환경이 향상되어 A형 간염 항체 양성률이 지난 20년 전보다 현저하게 감소되었다. 현재 소아 연령에서 A형 간염 항체 보유율이 매우 낮아 이들이 성인이 되는 경우 현증 A형 간염의 유행이 초래될 가능성이 높아지고 있다. 따라서 개인위생 및 생활환경을 개선하고, 고위험군을 대상으로 수동면역 및 능동면역을 시행하여 바이러스의 전파를 막아 A형 간염의 발생을 적극적으로 예방하여야 하겠다.

Keywords

References

  1. Hong WS, Kim JR. A seroepidemiologic study of hepatitis A and B infection in Seoul. Korean J Int Med 1982;25:19-26
  2. Yang DU, Lee YA, Sim JY, Park JY, Jung HL. Park MS, et al. A seroepidemiologic study on hepatitis A in Seoul, Korea. J Korea Pediatr Soc 1999;42:180-5
  3. Choi JW, Lee KI, Lee DZ, Han JH, Hang SS, Lee KS. Outbreak of hepatitis A in Taejon in 1996; clinical and epidemiologic study in children. Korean J Int Med 1997;4: 90-6
  4. Jung PJ, Kim DH, Joo IK, Park CH, Lee WS, Joo YE, et al. Clinical characteristics of sporadic hepatitis A in Gwangju- Jeonnam province. Korea J Hepatol 2005;11:65
  5. Derya A, Necmi A, Emre A, Akgun Y. Decline of maternal hepatitis a antibody during the first 2 years of life in infants born in Turkey. Am J Trop Med Hyg 2005;73:457-9
  6. De Silvestri A, Avanzini MA, Terulla V, Zucca S, Polatti F, Belloni C. Decline of maternal hepatitis A virus antibody levels in infants. Acta Paediatr 2002;91:882-4 https://doi.org/10.1080/080352502760148577
  7. Feinstone SM, Kapikian AZ, Purcell RH. Hepatitis A; detection by immune electron microscopy of a virus-like antigen associated with acute illness. Science 1973;182:1026-8 https://doi.org/10.1126/science.182.4116.1026
  8. Zachoval R, Kroener M, Deinharlt F. Serology and interferone production in patient with acute hepatitis A. J Infect Dis 1990;161:353-4
  9. Lee SD. Asian prospectives on viral hepatitis A. Journal of gastroenterology and hepatology 2000;15:94-9 https://doi.org/10.1046/j.1440-1746.2000.2047b.x
  10. Melnick JL. History and epidemiology of hepatitis A virus. J Infect Dis 1995;171:2-8 https://doi.org/10.1093/infdis/171.Supplement_1.S2
  11. Watson JC, Fleming DW, Borella AJ, Olcott ES, Conrad RE, Baron RC. Vertical transmission of hepatitis A resulting in an outbreak in a neonatal intensive care unit. J Infect Dis 1993;167:567-71 https://doi.org/10.1093/infdis/167.3.567
  12. Rosenblum LS, Villarino ME, Nainan OV. Hepatitis A outbreak in a neonatal intensive care unit; risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J Infect Dis 1991;164:476-82 https://doi.org/10.1093/infdis/164.3.476
  13. Skidmore SJ, Gully PR, Middleton JD, Hassam ZA, Singal GM. An outbreak of hepatitis A on a hospital ward. J Med Virol 1985;17:175-7 https://doi.org/10.1002/jmv.1890170210
  14. Chodick G, Ashkenazi S, Aloni H, Peled T, Lerman Y. Hepatitis A virus seropositivity among hospital and community healthcare workers in Israel:the role of occupation, demography and socioeconomic background. J Hosp Infect 2003; 54:135-40 https://doi.org/10.1016/S0195-6701(03)00124-5
  15. Serkan O, Selcen O, Serhan S. Hepatitis A and B seropisivity among medical students. Health Policy 2005;74:39-45 https://doi.org/10.1016/j.healthpol.2004.12.004
  16. Provost PJ, Wolanski BS, Muller IVJ, Ittensohn OL, McAleer WJ, Hillman MR. Physical, chemical, and morphological dimensions of human hepatitis A virus strain CR 326(38578). Proc Soc Exp Biol Med 1975;148:532-9
  17. Kim H, Kim JH, Kim DH, Heo JK, Lee WB, Seo BK, et al. Epidemiologic changes and clinical features of hepatitis A in children; living in Kyung-gi province, since 1988 to 1998. Korea J Pediatr Infect Dis 1998;5:230-6
  18. Duval B, De Serres G, Ochnio J, Scheifele D, Gilca V. Nationwide Canadian study of hepatitis A antibody prevalence among children eight to thirteen years old. J Pediatr Infect Dis 2005;24:514-9 https://doi.org/10.1097/01.inf.0000164705.74498.86
  19. Provost PJ, Itteson OL, Villarejos VM. A specific complement fixation test for human hepatitis A employing CR 326 virus antigen; diagnosis and epidemiology. Proc Soc Exp Biol Med 1975;149:263-4
  20. Purcell RH, Wong DC, Moritizu Y, Dienstag JL, Routenberg JA, Boggs JD. A microtiter solid-phase radioimmunoassay for hepatitis antigen and antibody. J Immunol 1976;116:349-56
  21. Bradely DW, Maynard JE, Kindman SH. Serodiagnosis of viral hepatitis A; detection of acute phase immunoglobulin M antihepatitis A virus by radioimmunoassay. J Clin Microbiol 1977;5:521-30
  22. Locarnini SA, Garland SM, Lehmann NL, Pringle RC, Gist ID. Solid-phase enzyme-linked immunosorbent assay for detection of hepatitis A virus. J Clin Microbiol 1978;8:277-82
  23. Decker RH, Overby LR, Ling CM, Frosner G, Deinharder F, Boggs J. Serologic studies of transmission of hepatitis A in humans. J Infect Dis 1979;139:74-82 https://doi.org/10.1093/infdis/139.1.74
  24. Lee CH. Hepatitis vaccination. Program and Abstract, the 48th Annual Fall Meeting of the Korean Association of Internal Medicine; 1996 Oct 25-26; Seoul. Seoul : The Korean Association of Internal Medicine, 1996:82-9
  25. Jung PJ, Kim DH, Joo IK, Park CH, Lee WS, Joo YE, et al. Clinical characteristics of sporadic hepatitis A in Gwangju- Jeonnam province. Korean J Hepatol 2005;11:65
  26. Stocks J Jr, Neefe JR. The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA 1945;127: 144-5 https://doi.org/10.1001/jama.1945.02860030016004
  27. Fujiyama S, Sasaki Y. Immune serum globulin and its usefulness for prevention of hepatitis A. Nippon Rinsho 2004; 62:496-8
  28. Winokur PL, Stepleton JT. Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis 1992;14:580-6 https://doi.org/10.1093/clinids/14.2.580
  29. Aszkenasy OM. A community outbreak of hepatitis A in a religious community in Indiana: failure of immune serum globulin to prevent the spread of infection. Epidemiol Infect. 2000;124:309-13 https://doi.org/10.1017/S0950268899003544
  30. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995;171:44-9 https://doi.org/10.1093/infdis/171.Supplement_1.S44
  31. Ashur Y, Adler R, Rowe M, Shouval D. Comparison of immunogenicity of two hepatitis A vaccines-VAQTA and HAVRIX-in young adults. Vaccine 1999;17:2290-6 https://doi.org/10.1016/S0264-410X(98)00480-0
  32. McMahon BJ, Williams J, Bulkow L. Immunogenecity of and inactivated hepatitis A vaccine in Alaska native children and native and non-native adults. J Infect Dis 1995;171: 676-9 https://doi.org/10.1093/infdis/171.3.676
  33. Korean Society of Pediatrics. Hepatitis A, Guidelines for vaccination, 5th ed. Kwangmoon Co 2002:223-32
  34. Van Damme P, Banatvala J, Fay O. Hepatitis A booster vaccination: is there a need? Lancet 2003;362:1065-71 https://doi.org/10.1016/S0140-6736(03)14418-2
  35. Im DS, Jo KH, Kim HC. A epidemiologic study of hepatitis A in the northwest area of Jeonbuk, Korea 1989. Korea J Internal Medicine 1992;43:57-63